Patents Assigned to MedImmune, LLC
  • METHODS TO MOLECULARLY CHARACTERIZE CIRCULATING TUMOR CELLS
    Publication number: 20110256155
    Abstract: The invention relates to a rapid, sensitive method to obtain a gene expression profile from a target cell population in a blood sample. The target cells can be circulating tumor cells. Disclosed are methods and kits for obtaining such profiles.
    Type: Application
    Filed: April 18, 2011
    Publication date: October 20, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: Jiaqi Huang, Haifeng Bao, Philip Brohawn, Patricia Burke, Xiaoru Chen, Theresa Lavallee, Yihong Yao
  • Influenza hemagglutinin and neuraminidase variants
    Patent number: 8039002
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: October 18, 2011
    Assignee: Medimmune, LLC
    Inventors: Chin-Fen Yang, George Kemble
  • IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES
    Publication number: 20110236406
    Abstract: The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specifically, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation.
    Type: Application
    Filed: January 18, 2011
    Publication date: September 29, 2011
    Applicants: MedImmune, LLC, The Feinstein Institute for Medical Research
    Inventors: Davorka Messmer, Kevin Tracey, Peter Kiener, Scott Alban
  • Molecules with extended half-lives, compositions and uses thereof
    Patent number: 8012476
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: September 6, 2011
    Assignees: MedImmune, LLC, Board of Regents, The University of Texas System
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
  • Methods of producing influenza vaccine compositions
    Patent number: 8012737
    Abstract: Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: September 6, 2011
    Assignee: Medimmune, LLC
    Inventors: Qi Dang, Richard Schwartz
  • Multi plasmid system for the production of influenza virus
    Patent number: 8012736
    Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: September 6, 2011
    Assignee: Medimmune, LLC
    Inventors: Erich Hoffman, Hong Jin, Bin Lu, Greg Duke, George Kemble
  • Modulation of antibody effector function by hinge domain engineering
    Patent number: 8008443
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or CIq. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: August 30, 2011
    Assignee: MedImmune, LLC
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casa-Finet
  • Stabilized liquid anti-RSV antibody formulations
    Patent number: 8007793
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: August 30, 2011
    Assignee: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • Influenza hemagglutinin and neuraminidase variants
    Patent number: 7981429
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: July 19, 2011
    Assignee: Medimmune, LLC
    Inventors: Chin-Fen Yang, George Kemble
  • METHODS OF PREVENTING AND TREATING RSV INFECTIONS AND RELATED CONDITIONS
    Publication number: 20110158985
    Abstract: The present invention provides methods for preventing, managing, treating and/or ameliorating a Respiratory Syncytial Virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), otitis media (preferably, stemming from, caused by or associated with a RSV infection, such as a RSV URI and/or LRI), and/or a symptom or respiratory condition relating thereto (e.g., asthma, wheezing, and/or reactive airway disease (RAD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity. In some embodiments, one or more antibodies comprise a modified IgG constant domain, or FcRn-binding fragment thereof resulting in longer in vivo serum half-life.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 30, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: GENEVIEVE LOSONSKY, EDWARD M. CONNOR, JAMES F. YOUNG, HERREN WU, WILLIAM DALL'ACQUA
  • High affinity antibodies against HMGB1 and methods of use thereof
    Patent number: 7964706
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: June 21, 2011
    Assignee: MedImmune, LLC
    Inventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian
  • ANTIBODIES WITH DECREASED DEAMIDATION PROFILES
    Publication number: 20110130544
    Abstract: The present invention relates to antibodies with decreased deamidation profiles, and methods for producing antibodies with decreased deamidation profiles.
    Type: Application
    Filed: March 25, 2008
    Publication date: June 2, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: Kripa Ram, Raghavan Venkat
  • SWINE INFLUENZA HEMAGGLUTININ VARIANTS
    Publication number: 20110123559
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Application
    Filed: June 24, 2010
    Publication date: May 26, 2011
    Applicant: MEDIMMUNE, LLC
    Inventor: Hong JIN
  • CRYSTALS AND STRUCTURE OF HUMAN IgG Fc VARIANT
    Publication number: 20110091992
    Abstract: The present invention provides crystalline forms of a human IgG Fc variant comprising one or more amino acid residues that provides for enhanced effector function, methods of obtaining such crystals and high-resolution X-ray diffraction structures and atomic structure coordinates. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of the human IgG Fc variant and methods of using them. The present invention also provides human IgG Gc variants with reduced binding to at least one Fc?R.
    Type: Application
    Filed: July 10, 2008
    Publication date: April 21, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: William Dall'Acqua, Vaheh Oganesyan, Jose Casas-Finet, Bradford Braden, Herren Wu
  • METHODS OF ADMINISTERING/DOSING CD2 ANTAGONISTS FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISORDERS OR INFLAMMATORY DISEASES
    Publication number: 20110091453
    Abstract: The present invention provides compositions for the prevention or treatment of an autoimmune disorder or an inflammatory disorder in a subject comprising one or more CD2 antagonists. In particular, the invention provides methods for preventing or treating an autoimmune disorder or an inflammatory disorder in a subject comprising administering one or more CD2 binding molecules to said subject. The present invention provides doses of CD2 binding molecules and methods of administration that result in improved efficacy, while avoiding or reducing the adverse or unwanted side effects associated with the administration of an agent that induces the depletion of peripheral blood lymphocytes.
    Type: Application
    Filed: December 8, 2009
    Publication date: April 21, 2011
    Applicant: MEDIMMUNE, LLC
    Inventor: Christine Dingivan
  • Spray freeze dry of compositions for pulmonary administration
    Patent number: 7923029
    Abstract: This invention provides methods and compositions to preserve bioactive materials, such as viruses, bacteria, cells, or liposomes, in freeze dried particles suitable for pulmonary administration. Methods provide spray freeze drying of formulations to form stable freeze dried particles.
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: April 12, 2011
    Assignee: MedImmune LLC
    Inventors: Vu Truong-Le, Binh V. Pham, John F. Carpenter, Robert Seid, Theodore W. Randolph
  • ANTIBODY LIBRARY DISPLAY BY YEAST CELL PLASMA MEMBRANE
    Publication number: 20110076752
    Abstract: The present invention relates to antibodies or antibody fragments that may be displayed on the extracellular surface of the plasma membrane when expressed in a host cell. The present invention provides libraries comprising a plurality of plasma membrane displayed antibodies and methods of screening the libraries for antibodies or antibody fragments with desired characteristics.
    Type: Application
    Filed: February 8, 2008
    Publication date: March 31, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: Herren Wu, Changshou Gao
  • HINGE DOMAIN ENGINEERING
    Publication number: 20110077383
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which improves stability and/or alters the binding of Fc to one or more metal ion and/or one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that are less susceptible to metal ion-mediated cleavage and/or have modified binding affinity to one or more Fc?R and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. Furthermore, the modified hinge of the Fc variants retains a similar flexibility to the wild type hinge. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Application
    Filed: July 2, 2008
    Publication date: March 31, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casas-Finet, Raul Cachau
  • INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS
    Publication number: 20110070263
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Application
    Filed: August 17, 2010
    Publication date: March 24, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: Chin-Fen Yang, George Kemble, Chongguang Liu
  • NON-SPLICING VARIANTS OF GP350/220
    Publication number: 20110059486
    Abstract: Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins.
    Type: Application
    Filed: March 3, 2010
    Publication date: March 10, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: Richard SPAETE, Winthrop JACKMAN